AARTIDRUGSBSEAarti Drugs LtdMinimalNeutral
Announced Tue, 26 May · 20:55 IST

Annual Secretarial Compliance Report for the financial year ended March 31, 2026

AARTIDRUGS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-3.5%1-day move
₹392.70
prior close
₹394.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.8+0.2+0.1+0.1-3.5-2.3-3.1-3.6-4.5-7.0-6.0-4.5+4.4
Up moveDown movePending
AI summary

Aarti Drugs Limited has submitted its Annual Secretarial Compliance Report for FY 2025-26, certified by Mehta & Mehta, Practising Company Secretaries. The report confirms the company complied with all applicable SEBI regulations including LODR, Substantial Acquisition of Shares and Takeovers, and Insider Trading regulations. One observation was noted: the company delayed intimation to stock exchanges regarding a Maharashtra Pollution Control Board (MPCB) direction dated July 2025 concerning pollution control operations at its Tarapur unit. The company received cautionary letters from BSE and NSE for this delay. Management responded that corrective steps will be taken to avoid recurrence. All 13 compliance checkpoints including secretarial standards, RPTs, insider trading, and document preservation showed 'Yes' compliance status.

Likely market impact

Overall positive for shareholders as the company maintained regulatory compliance throughout the year with only one minor procedural delay in stock exchange intimation. The cautionary letters from exchanges were addressed and no material regulatory actions were taken against the company.